CMND
NASDAQClearmind Medicine Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News25/Ratings0
News · 26 weeks99-6%
2025-12-282026-06-21
Mix5890d
- SEC Filings29(50%)
- Other24(41%)
- Insider5(9%)
Latest news
25 items- SECSEC Form 6-K filed by Clearmind Medicine Inc.6-K - Clearmind Medicine Inc. (0001892500) (Filer)
- PRClearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II TrialVancouver, Canada, June 22, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of treatment for all participants in Part A of its ongoing Phase I/II clinical trial evaluating CMND-100 for the treatment of Alcohol Use Disorder (AUD). All 24 participants across Cohorts 1 through 4 have successfully completed treatment according to the study protocol. The Company is currently assessing the dataset and, a
- SECSEC Form EFFECT filed by Clearmind Medicine Inc.EFFECT - Clearmind Medicine Inc. (0001892500) (Filer)
- INSIDERLarge owner Hrt Financial Lp sold $73,192 worth of Class A Shares (22,139 units at $3.31), decreasing direct ownership by 21% to 81,353 units (SEC Form 4)4 - Clearmind Medicine Inc. (0001892500) (Issuer)
- SECSEC Form 6-K filed by Clearmind Medicine Inc.6-K - Clearmind Medicine Inc. (0001892500) (Filer)
- PRClearmind Medicine Granted U.S. Patent for Binge Behavior RegulatorsVancouver, Canada, June 18, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogens-derived therapeutics to solve major under-treated health problems, today announced that it has been granted a U.S. Patent, No. 12,350,242, titled "BINGE BEHAVIOR REGULATORS", by the United States Patent and Trademark Office (USPTO). The patent, which refers to Clearmind's molecule MEAI (5-methoxy-2-aminoindane), covers innovative compositions and methods utilizing a pharmaceutically acceptable salt to regulate binge behaviors, inc
- INSIDERLarge owner Hrt Financial Lp sold $10,568 worth of shares (3,183 units at $3.32), decreasing direct ownership by 3% to 103,492 units (SEC Form 4)4 - Clearmind Medicine Inc. (0001892500) (Issuer)
- INSIDERLarge owner Hrt Financial Lp sold $7,063 worth of shares (2,102 units at $3.36), decreasing direct ownership by 2% to 106,675 units (SEC Form 4)4 - Clearmind Medicine Inc. (0001892500) (Issuer)
- SECSEC Form 6-K filed by Clearmind Medicine Inc.6-K - Clearmind Medicine Inc. (0001892500) (Filer)
- PRClearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical TrialVancouver, Canada, June 16, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of dosing for all 24 participants in Cohorts 1 through 4 of Part A of its ongoing Phase I/II clinical trial evaluating CMND-100 for the treatment of Alcohol Use Disorder (AUD). All healthy participants in the first stage of the trial have been treated with escalating dose levels of the Company's proprietary drug candidate,
- SECSEC Form POS AM filed by Clearmind Medicine Inc.POS AM - Clearmind Medicine Inc. (0001892500) (Filer)
- SECSEC Form 6-K filed by Clearmind Medicine Inc.6-K - Clearmind Medicine Inc. (0001892500) (Filer)
- INSIDERLarge owner Hrt Financial Lp bought $330,335 worth of shares (2,159,052 units at $0.15) and sold $27,698 worth of shares (225,191 units at $0.12) (SEC Form 4)4 - Clearmind Medicine Inc. (0001892500) (Issuer)
- INSIDERNew insider Hrt Financial Lp claimed ownership of 101,951 shares (SEC Form 3)3 - Clearmind Medicine Inc. (0001892500) (Issuer)
- SECSEC Form 6-K filed by Clearmind Medicine Inc.6-K - Clearmind Medicine Inc. (0001892500) (Filer)
- PRClearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on "Inside MEAI" WebinarRegister now for free and join on June 10, 2026 Vancouver, Canada, June 05, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced it will host a live webinar titled "Inside MEAI: Exclusive Investigator Q&A with Yale & Johns Hopkins on Wednesday, June 10, 2026, from 12:00–1:00 PM EDT (9:00–10:00 AM PDT). Interested participants are invited to register and secure their spot in this exclusive session. The webinar will provide an in-
- SECSEC Form 6-K filed by Clearmind Medicine Inc.6-K - Clearmind Medicine Inc. (0001892500) (Filer)
- SECSEC Form 6-K filed by Clearmind Medicine Inc.6-K - Clearmind Medicine Inc. (0001892500) (Filer)
- PRClearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression TreatmentVancouver, Canada, May 29, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second-generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the publication of a Japanese Patent Application for its proprietary compositions comprising 5-Methoxy-2-aminoindan (MEAI) for the treatment of depression. This advancement strengthens Clearmind's robust intellectual property portfolio, which already includes multiple granted patents and applications worldwide. MEAI, the company's flagship non-halluc
- PRClearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next PartsVancouver, Canada, May 26, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second-generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that the Johns Hopkins Medicine Institutional Review Board (JHM-IRB) has granted approval for its ongoing Phase I/II clinical trial of CMND-100. The approval advances the multicenter study titled "A Phase I/II Single and Multiple Dose Tolerability, Safety and Pharmacokinetic Study of CMND-100 in Healthy Volunteers and Alcohol Use Disorder (AUD) Subjec
- SECSEC Form 6-K filed by Clearmind Medicine Inc.6-K - Clearmind Medicine Inc. (0001892500) (Filer)
- SECSEC Form 6-K filed by Clearmind Medicine Inc.6-K - Clearmind Medicine Inc. (0001892500) (Filer)
- SECSEC Form 6-K filed by Clearmind Medicine Inc.6-K - Clearmind Medicine Inc. (0001892500) (Filer)
- PRClearmind Medicine Announces 1-for-10 Reverse Share SplitVancouver, Canada, May 19, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that it will conduct a reverse share split of its issued and outstanding common shares, no par value, at a ratio of 1-for-10. The reverse split is being effected as part of the Company's plan to regain compliance with the Nasdaq Minimum Bid Price Rule and will be effective commencing May 21, 2026. The reverse share split was approved by the Company'
- SECSEC Form 6-K filed by Clearmind Medicine Inc.6-K - Clearmind Medicine Inc. (0001892500) (Filer)
CMND FAQ
4 questionsWhere does CMND stock trade?
Clearmind Medicine Inc. (CMND) is listed on NASDAQ.What sector and industry is CMND in?
Clearmind Medicine Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to CMND?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare CMND side-by-side with any of them on Quantisnow.How can I track CMND on Quantisnow?
Quantisnow aggregates Clearmind Medicine Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CMND to receive live email and push alerts on every new disclosure.